SCHEMBL2811577

SCHEMBL2811577

CC(C)(C)OC(=O)C1(Cc2ccccc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA7 P43166 1/20 0.41
CA14 Q9ULX7 1/20 0.41
ALDH1A1 P00352 3/20 0.41
P4HB P07237 1/20 0.41
KDM4E B2RXH2 2/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
HTT P42858 1/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
AKT1 P31749 2/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17181077 0.89 LMNA (0.47) LMNASMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL1003120 0.87 LMNA (0.50) LMNASMN1; SMN2ALDH1A1P4HBKDM4E
SCHEMBL15111424 0.86 LMNA (0.45) LMNASMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL9313155 0.86 CTSS (0.39) LMNASMN1; SMN2ALDH1A1P4HBKDM4E
SCHEMBL2535174 0.84 CA12 (0.44) LMNACA12CA1CA7CA14
SCHEMBL1177978 0.84 CTSB (0.43) ALDH1A1KMT2AMEN1L3MBTL1
SCHEMBL4029213 0.83 LMNA (0.57) LMNASMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL1178865 0.83 MEN1 (0.39) LMNAALDH1A1P4HBKMT2AMEN1
SCHEMBL30749948 0.83 MEN1 (0.39) LMNAALDH1A1P4HBKMT2AMEN1
SCHEMBL1177815 0.82 FFAR1 (0.44) LMNACA12CA1CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9595734-B2 Non-aqueous liquid electrolyte for secondary battery and secondary battery FUJIFILM CORPORATION (JP) 2017-03-14 US disclosed
US-9595734-B2 Non-aqueous liquid electrolyte for secondary battery and secondary battery FUJIFILM CORPORATION (JP) 2017-03-14 US disclosed
US-20140234729-A1 NON-AQUEOUS LIQUID ELECTROLYTE FOR SECONDARY BATTERY AND SECONDARY BATTERY FUJIFILM CORPORATION (JP) 2014-08-21 US disclosed
US-8362040-B2 4-phenylpiperidine derivatives as renin inhibitors NOVARTIS AG (CH) 2013-01-29 US disclosed
US-20100240679-A1 4-Phenylpiperidine Derivatives as Renin Inhibitors NOVARTIS AG (CH) 2010-09-23 US disclosed
US-7754727-B2 4-phenylpiperidine derivatives as renin inhibitors NOVARTIS AG (CH) 2010-07-13 US disclosed
EP-1689712-B1 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-08-19 EP disclosed
US-20080269255-A1 4-Phenylpiperidine Derivatives as Renin Inhibitors NOVARTIS AG (CH) 2008-10-30 US disclosed
US-20070078164-A1 4-Phenylpiperidine derivatives as renin inhibitors SEDRANI RICHARD 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269255-A1 4-Phenylpiperidine Derivatives as Renin Inhibitors REN, AGTR1, ACE LMNA 1346/4885SMN1; SMN2 3235/4885CA12 4117/4885
US-20100240679-A1 4-Phenylpiperidine Derivatives as Renin Inhibitors REN, AGTR1, ACE LMNA 1618/4885SMN1; SMN2 3512/4885CA12 4280/4885
US-20070078164-A1 4-Phenylpiperidine derivatives as renin inhibitors REN, AGTR1, ACE LMNA 1618/4885SMN1; SMN2 3512/4885CA12 4280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.